Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (TSE:BCT)
TSX:BCT
BriaCell Therapeutics (BCT) Stock Price & Analysis
27 Followers
BCT Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.86 - C$10.29
Previous CloseC$0.97
Volume12.76K
Average Volume (3M)12.87K
Market Cap
C$17.18M
Enterprise ValueC$8.07M
Total Cash (Recent Filing)$6.24M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Oct 24, 2024EPS EstimateN/A
Last Dividend Ex-Date
Sep 05, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding15,981,726
10 Day Avg. Volume4,375
30 Day Avg. Volume12,868
Standard Deviation0.27
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-2.31
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
C$24.81Price Target Upside2431.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
BriaCell Therapeutics News
PremiumCompany Announcements
BriaCell Touts Breakthrough in Breast Cancer Survival
PremiumCompany Announcements
BriaCell Subsidiary BriaPro Releases Financial ReportsPremiumCompany Announcements
BriaCell’s Bria-IMT™ Shows Promise for Breast Cancer
PremiumCompany Announcements
BriaCell Launches Trial for Breast Cancer ImmunotherapyBCT FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was C$0.86 and its highest was C$10.29 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
Currently, no data Available
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Oct 24, 2024 which is in 92 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Jun 14, 2024. The company reported C$0.146 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.146.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Undervalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp pays a Notavailable dividend of C$0.09 which represents an annual dividend yield of N/A. See more information on BriaCell Therapeutics Corp dividends here
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 18,284,660 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of C$0.146 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.233%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:BCT
---
BriaCell Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$24.81 (2431.63% Upside)
C$24.81 (2431.63% Upside)
Blogger Sentiment
Bullish
TSE:BCT Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth C$5.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-78.86%
Trailing 12-Months
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.
---
BCT Stock 12 Month Forecast
Average Price Target
C$24.81
▲(2431.63% Upside)
Technical Analysis
Best Analysts Covering BCT
1 Year
1 Year Success Rate
3/19 ratings generated profit
1 Year Average Return
-46.45%
reiterated a buy rating 2 months ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 15.79% of your transactions generating a profit, with an average return of -46.45% per trade.
---